Succession Planning Venture-Backed Founders UK-US Guide |

Succession Planning Venture-Backed Founders UK-US Guide |

Succession Planning Venture-Backed Founders: UK-US Guide

Succession Planning for Venture-Backed Founders Across the UK-US

A venture-backed founder who dies while holding a significant equity stake in a Series B startup faces a succession problem that very few estate planners have encountered: the shares may be worth tens of millions of pounds on paper, but they are entirely illiquid, subject to investor rights that restrict transfers to family members, and caught between UK inheritance tax rules that may or may not recognise business property relief and a US estate tax regime that values the shares at their date-of-death fair market value regardless of the transfer restrictions that make those shares practically unsaleable. For a U.S. citizen founder who is a U.K. resident, the succession planning venture-backed founders founders sits at the intersection of two of the most complex tax systems in the world, applied to an asset class — venture equity — that neither system was designed to handle well. The result is that most founders in dual UK-US situations reach Series B or Series C without any succession plan at all, leaving their families exposed to a combined tax bill that can force a distressed sale of the very shares that the estate plan was designed to protect.

This article is written for U.S. citizen founders who are UK residents, hold venture-backed startup equity in UK or US companies, and have not yet addressed the estate-planning implications of that equity. By the end of this guide, you will understand the specific tax challenges that succession planning venture-backed founders face across both the UK and US systems, the trust structures that can address those challenges before a liquidity event, and the most common planning mistakes that leave founder estates significantly worse off than they need to be.

What Is Succession Planning for Venture-Backed Founders?

Succession planning for venture-backed founders is the process of structuring a founder's equity holdings, lifetime gifts, and trust arrangements in a way that minimises the combined UK IHT and US estate tax exposure on startup shares, protects the founder's family from a forced share sale to meet a tax bill, and ensures that the equity passes to the intended beneficiaries without triggering unnecessary tax events at death or on any earlier liquidity event. Furthermore, for a UK-resident US-citizen founder, this requires simultaneous planning across two entirely separate estate tax regimes — the UK IHT regime, which taxes the worldwide estate of a long-term UK resident at 40% above the nil-rate band, and the US federal estate tax under IRC Chapter 11, which taxes the worldwide estate of a US citizen at up to 40% above the unified credit regardless of their country of residence. Specifically, the most difficult aspect of succession planning venture-backed founders in a dual UK-US context is that the two regimes apply the same 40% rate to the same assets — the venture equity — through different valuation methodologies, different reliefs, and different timing rules, making the combined tax exposure greater than either regime alone would produce without the US-UK Estate and Gift Tax Treaty credit mechanism to provide partial relief. The HMRC guidance on IHT business property relief for unlisted shares is at https://www.gov.uk/hmrc-internal-manuals/inheritance-tax-manual/ihtm25261.

Why Founder Succession Planning Matters More in 2026

The FA 2025 IHT Reforms and Worldwide Estate Exposure

The Finance Act 2025 abolished the UK non-domicile regime from April 2025, bringing all long-term UK residents — including US-citizen founders who had previously been non-domiciled — into the scope of UK IHT on their worldwide estates. Furthermore, this change is particularly significant for US-citizen founders of US-incorporated startups — Delaware C-corps, for example — since those US company shares were previously outside the UK IHT net under the old non-domicile excluded property rules but are now subject to UK IHT under the new residence-based regime where the founder has been UK resident for more than ten years. Consequently, a US-citizen founder who holds 20% of a UK-based Series B startup valued at £50 million — a stake worth approximately £10 million — now faces a combined UK IHT and US estate tax exposure on those shares that could represent more than £4 million of tax liability at current rates, before any business property relief analysis. According to https://www.icaew.com, the FA 2025 changes to the IHT treatment of worldwide estates represent the most significant shift in UK international estate planning since the introduction of the deemed domicile rules in 2017.

The Business Property Relief Uncertainty for Venture Equity

Business property relief provides a 100% IHT exemption for relevant business property — including unquoted shares in trading companies — but the availability of BPR for venture-backed startup equity is not as straightforward as many founders assume. Furthermore, BPR is denied where the company's business consists wholly or mainly of holding investments, dealing in securities, or dealing in land — and some startup structures, particularly those with significant cash holdings from recent funding rounds, may face an HMRC challenge to their BPR eligibility on the basis that the cash position means the company's business is partly investment rather than wholly trading. Consequently, a founder's estate that relies on BPR to eliminate the IHT on startup equity without having obtained a prior BPR opinion — or without having addressed the cash-to-trading ratio in the company's accounts — faces an HMRC inquiry into the BPR claim that can result in a significantly higher IHT liability than the estate plan assumed. The HMRC BPR guidance is at https://www.gov.uk/hmrc-internal-manuals/inheritance-tax-manual/ihtm25261.

The US Estate Tax Valuation of Restricted Startup Shares

For US estate tax purposes, the founder's startup shares are valued at their date-of-death fair market value — which for a venture-backed company is typically calculated by reference to the most recent funding round price, adjusted for any marketability or minority interest discounts that a qualified business valuator can support. Furthermore, the restricted nature of the founder's shares — which are typically subject to investor consent rights for transfers, right-of-first-refusal provisions, and co-sale rights that effectively prevent the family from selling the shares following a founder's death without investor approval — can support a significant discount from the headline funding round valuation for US estate tax purposes. Consequently, a properly supported valuation discount of 20-35% on the founder's shares can produce a meaningful reduction in the US estate tax on the equity, and succession planning venture-backed founders should include commissioning a qualified IRS Section 409A-methodology valuation as part of the estate-planning package rather than waiting until death.

Trust Structures for UK-US Founder Succession Planning

The Irrevocable Trust and Section 409A Considerations

An irrevocable trust established by the US-citizen founder during their lifetime — transferring startup equity to the trust before a Series B or C funding round — can remove the shares from both the UK IHT estate and the US gross estate, provided the founder does not retain a taxable interest in the trust under IRC Sections 2036 and 2038 or under the UK gift with reservation of benefit rules. Furthermore, the transfer of startup equity to an irrevocable trust is a potentially exempt transfer for UK IHT purposes — starting the seven-year clock running on the IHT exemption — and a completed gift for US gift tax purposes, requiring Form 709 reporting in the year of the transfer. Specifically, the timing of the trust settlement relative to the company's funding rounds is critical — settling shares at a lower pre-round valuation produces a lower gift tax value and a lower UK IHT value for the seven-year PET calculation — making the trust settlement most tax-efficient at the earliest possible stage of the company's development, before institutional investors have driven the valuation upward. The IRS guidance on transfer tax treatment of business interests is at https://www.irs.gov/businesses/small-businesses-self-employed/frequently-asked-questions-on-gift-taxes.

The Intentionally Defective Grantor Trust for US Founders

An intentionally defective grantor trust — a trust intentionally structured to be a grantor trust for US income tax purposes while remaining outside the US taxable estate — is a widely used US estate planning vehicle with specific advantages for founder equity. Furthermore, the IDGT structure allows the founder to continue paying income tax on the trust's income — including any capital gain on a future sale of the startup shares within the trust — as if the income arose to the founder personally, which is effectively a tax-free gift to the trust beneficiaries equal to the income tax the founder pays each year on the trust's income. Additionally, for a UK-resident US-citizen founder, the IDGT must be analyzed under both the US grantor trust rules — to confirm it achieves the intended income tax treatment — and the UK settlor-interested trust rules — to confirm it does not inadvertently trigger the UK income tax attribution that applies where the settlor can benefit from the trust. Consequently, the IDGT structure requires a specific dual-jurisdiction legal and tax analysis to confirm that the intended US income tax treatment and the intended UK IHT estate exclusion are achieved simultaneously.

EIS Relief and Its Interaction with Trust Settlements

Where the founder holds shares in a company that qualifies for Enterprise Investment Scheme relief, those shares benefit from IHT relief after being held for two years — since EIS-qualifying shares are relevant business property for BPR purposes. Furthermore, a gift of EIS shares to a trust within the two-year holding period results in a chargeable transfer for IHT purposes rather than a potentially exempt transfer — thereby losing the BPR protection that would have been available had the shares been held for two years before any transfer. Additionally, EIS shares gifted to a trust trigger a clawback of the EIS income tax relief claimed by the founder on the original investment — since the EIS income tax relief is conditional on the founder retaining the shares for three years from the date of issue. Consequently, succession planning venture-backed founders for EIS shareholders must be timed carefully around the two-year BPR qualifying period and the three-year EIS income tax relief clawback period to avoid triggering clawback charges that reduce the net benefit of the estate planning. The HMRC EIS guidance is at https://www.gov.uk/guidance/enterprise-investment-scheme-relief.

Building a Founder Succession Plan: Practical Steps

Step 1 — Map the equity structure and vesting schedule.

Obtain the cap table for the founder's company, the shareholder agreement, the articles of association, and the vesting schedule for all founder shares — confirming the number of shares vested and unvested, the transfer restrictions in the shareholder agreement, and any drag-along, tag-along, or co-sale provisions that affect the transferability of the founder's equity at death. Furthermore, confirm whether any of the founder's shares are subject to EMI options or unapproved share options that create a different succession treatment on death — since unvested options typically lapse at death rather than passing to the estate, while vested options may or may not be exercisable by the estate depending on the scheme rules. Additionally, confirm the current 409A valuation date and methodology, since the most recent independent valuation is the starting point for the US gift tax value of any lifetime transfer of shares to a trust. The IRS guidance on valuation of business interests for estate and gift tax is at https://www.irs.gov/pub/irs-pdf/p561.pdf.

Step 2 — Assess BPR eligibility and the cash-to-trading ratio.

Review the company's most recent accounts and the current cash position relative to the company's trading activities to confirm whether the company would satisfy the BPR wholly-or-mainly-trading test at the current date — since a company with a significant cash balance from a recent funding round may argue that its business is partly investment activity. Furthermore, where the cash position is a concern, consider whether the company can deploy the cash into trading activities before the next BPR assessment date — either through operating expenditure or through investments in qualifying assets — to improve the trading-to-investment ratio. Additionally, obtain a written BPR opinion from a qualified tax adviser before the succession plan relies on BPR as its primary IHT mitigation strategy, since an undocumented BPR claim that HMRC challenges at death can produce a significantly higher IHT bill than the estate plan assumed.

Step 3 — Commission a valuation with appropriate discounts.

Commission a qualified business valuation of the founder's equity stake at the current date — using a 409A methodology for US purposes and a fair market value methodology for UK purposes — incorporating all applicable discounts for lack of marketability, minority interest, and transfer restrictions under the company's shareholder agreement. Furthermore, document the valuation methodology and assumptions in a written report that can be presented to both HMRC and the IRS in the event of a challenge to the gift tax or estate tax value of the shares, since an unsupported valuation is the most common target of IRS and HMRC estate tax inquiries for illiquid business interests. Additionally, update the valuation annually or at each major funding round, since the IRS may not accept a valuation more than 12 months old as a contemporaneous, arm's-length determination of fair market value.

Step 4 — Establish the trust structure and make the lifetime transfer.

Execute the trust deed and transfer the founder's shares to the trust at the current independently determined fair market value, filing Form 709 in the year of the transfer, reporting the gift of shares at the discounted valuation, and using any available annual exclusion and lifetime exemption to reduce or eliminate the US gift tax. Furthermore, confirm the UK IHT treatment of the transfer — whether it is a potentially exempt transfer (zero IHT if the founder survives seven years) or a chargeable lifetime transfer (IHT at 20% on the value above the nil-rate band at the date of transfer) — depending on whether the trust is a bare trust, a qualifying interest in possession trust, or a discretionary trust. Additionally, ensure that the trust deed is drafted to avoid the UK gift with reservation of benefit rules and the UK settlor-interested trust rules — since either of these would cause the shares to remain in the founder's UK IHT estate or be attributed back to the founder for UK income tax purposes despite the lifetime transfer.

Step 5 — Coordinate the US and UK annual compliance for the trust.

Establish an annual compliance program for the trust that produces Form 3520-A for the US trustee, the UK self-assessment return for the trust's income, the FBAR for the trust's financial accounts where applicable, and the annual confirmation that the trust's shares have not been transferred or diluted in a way that changes the tax analysis. Furthermore, where the founder retains the right to repurchase unvested shares from departing employees — through standard bad-leaver provisions — this confirms that those repurchases do not constitute a taxable event under US or UK rules that would affect the trust's compliance position. Additionally, update the valuation each year for Form 3520-A purposes and confirm the BPR eligibility of the trust's shareholding each year for UK IHT periodic charge purposes, since the trust's shares are relevant business property for the IHT periodic charge calculation on each ten-year anniversary of the trust.

Case Study: US Founder in London, Series B Succession Plan

Our team was engaged by a U.S. citizen founder who had lived in London for 9 years and held 18% of a UK-incorporated Series B SaaS company valued at £45 million in its most recent round — representing a stake worth approximately £8.1 million. The founder's shares were fully vested, held under the company's articles without any EMI or options, and subject to standard investor consent and right-of-first-refusal provisions in the shareholder agreement. The founder had no will, no trust structure, and no estate plan of any kind. His spouse was a UK national with no US connection.

After reviewing the position, we identified that the FA 2025 changes meant the founder's worldwide estate — including his UK startup shares and a US investment portfolio of approximately $420,000 — was fully within the scope of UK IHT as a long-term UK resident. Furthermore, the UK IHT on the startup shares at death would be 40% of £8.1 million above the nil-rate band — approximately £3.1 million of IHT — unless BPR was available to exempt the shares as relevant business property. Additionally, we obtained a BPR opinion confirming eligibility — the company was a trading SaaS business with a cash position of approximately 12% of total assets, well within the trading threshold — meaning BPR would exempt the shares from UK IHT entirely if the founder held them at death.

For the US estate tax position, we commissioned a 409A-methodology valuation of the founder's 18% stake incorporating a 25% discount for lack of marketability and minority interest, reducing the US estate tax value from £8.1 million to approximately £6.1 million ($7.7 million at current exchange rates). Furthermore, with the US unified credit of approximately $13.61 million available, no US estate tax would be due on the startup shares even at the undiscounted value — making the US estate tax analysis less urgent than the UK IHT analysis for this particular client. Additionally, we drafted a UK will leaving the startup shares directly to the founder's spouse under the UK spousal exemption for immediate IHT relief, with the shares passing to the couple's children on the spouse's subsequent death — potentially with a further BPR exemption at that stage. The total cost of the succession plan — legal fees, valuation, and annual compliance — was approximately £18,000, compared with a potential unplanned UK IHT liability of £3.1 million.

Common Mistakes in Founder Succession Planning

Mistake 1 — Relying on BPR Without Getting a Prior Opinion

Many founders assume that their startup shares automatically qualify for 100% BPR without obtaining a written opinion confirming that the company satisfies the wholly-or-mainly-trading test. Furthermore, a cash-heavy post-round balance sheet, a subsidiary engaged in investment activities, or a holding company structure can all undermine BPR eligibility in ways that are not apparent from the company's headline description as a technology company. The correct approach requires a specific BPR opinion at each funding round — since the company's asset composition changes materially at each round — rather than a single opinion obtained at incorporation. HMRC BPR guidance is at https://www.gov.uk/hmrc-internal-manuals/inheritance-tax-manual/ihtm25261.

Mistake 2 — Waiting Until a Liquidity Event to Start Planning

The most common succession planning mistake for venture-backed founders is deferring trust settlement and lifetime gifts until the company is about to IPO or be acquired — at which point the shares are valued at or near their peak value, if maximizing the tax cost of any lifetime transfer is maxeven-year UK PET clock has no time to run before the shares are converted to cash. Furthermore, lifetime transfers of founder equity are most tax-efficient at the earliest stages of the company's development — pre-Series A, before institutional investors have established a high valuation — when the gift tax value of the shares is at its lowest, and the seven-year clock has the most time to complete. The correct approach requires succession planning to begin as a first-principles exercise at company formation, not as a reactive exercise when a liquidity event is imminent.

Mistake 3 — Not Considering the Investor Consent Requirements

Most venture shareholder agreements require investor consent for any transfer of founder shares — including transfers to family trusts — and many founders discover this restriction for the first time when they attempt to implement a trust settlement. Furthermore, investor consent is not always obtainable, and some shareholder agreements explicitly prohibit transfers to trusts in which the founder has any beneficial interest. The correct approach requires the founder's legal adviser to review the shareholder agreement's transfer restriction provisions before any trust settlement is proposed, to confirm whether investor consent is required and whether it is likely to be granted given the proposed trust structure.

Mistake 4 — Not Updating the Will to Reflect the Equity Structure

A founder who holds significant startup equity and who has a generic will drafted before the company reached a meaningful valuation may have a will that does not address the specific succession issues raised by the venture equity — including the BPR analysis, the investor consent requirements for transfers at death, and the potential forced sale to meet IHT where BPR is not available. Furthermore, many founders have no will at all — meaning their estate would pass under the intestacy rules, which may direct the shares to the surviving spouse (triggering the spousal exemption for UK IHT) but which do not allow for any of the trust structures that could protect the shares for the next generation. The correct approach requires a venture-specific will review at each major funding round, with the IHT analysis and the investor consent analysis updated alongside the company's valuation.

Mistake 5 — Not Coordinating EIS Relief with the Succession Plan

Founders who hold EIS shares in the company — through qualifying investments rather than through founder equity — and who gift those shares to a trust within the three-year EIS income tax relief clawback period face an unexpected income tax bill on the clawback at the time of the gift. Furthermore, the interaction among the EIS clawback, the BPR two-year qualifying period, and the UK PET seven-year clock creates a complex timing analysis that must be managed over multiple years for the succession plan to achieve all its objectives. The correct approach requires the succession plan to map all relevant holding periods across EIS, BPR, and PET before any lifetime transfer is made, to confirm the optimal timing of the trust settlement. HMRC EIS guidance is at https://www.gov.uk/guidance/enterprise-investment-scheme-relief.

Get in Touch

At US-UK Tax, our team of Chartered Tax Advisers (CTA), Enrolled Agents (EA), and Certified Public Accountants (CPA) — members of the Chartered Institute of Taxation (CIOT) and the American Institute of CPAs (AICPA) — provides succession planning venture-backed founders advice for UK-resident US-citizen founders across the full lifecycle of a venture-backed company, from formation through Series B, C, and liquidity events. Furthermore, we coordinate the UK IHT analysis — BPR eligibility, PET timing, trust structure, and will drafting — with the US estate and gift tax planning — lifetime trust settlements, Form 709 gift tax reporting, US estate tax valuation methodology, and the US-UK treaty credit at death — in a single integrated engagement that ensures the two systems' requirements are addressed simultaneously and consistently. We work alongside the founder's legal advisers and the company's corporate lawyers to ensure the succession plan is consistent with the shareholder agreement's transfer restrictions and the investors' consent requirements.

Contact our team today to begin a confidential founder succession planning review. Email hello@us-uktax.com, call 0333-8807974, or visit https://www.us-uktax.com/contact/.

Conclusion

Trust and succession planning venture-backed founders in a UK-US cross-border context is one of the most complex and most time-sensitive areas of wealth planning — because the value of the equity, the timing of any lifetime transfer, and the BPR eligibility of the shares all change materially at each funding round, making the optimal succession plan highly dependent on the specific stage of the company and the specific composition of the founder's equity. Furthermore, the FA 2025 changes have brought US-citizen founders' worldwide startup equity into the UK IHT net for the first time — including US-incorporated company shares that were previously excluded as non-UK assets — dramatically expanding the estate tax exposure that a cross-border succession plan must address. Moreover, the combination of BPR uncertainty, investor consent restrictions, and the seven-year PET clock makes early planning — before the company reaches its peak valuation — significantly more tax-efficient than reactive planning at the point of a liquidity event.

The three most important actions for any UK-resident US-citizen venture-backed founder are: first, obtain a BPR opinion on the company's shares at the current stage of the company's development — confirming eligibility before the succession plan relies on it as its primary IHT mitigation tool; second, consider a lifetime trust settlement of founder equity at the earliest stage when the valuation is lowest, maximising the seven-year PET benefit and minimising the gift tax value; and third, review the shareholder agreement's transfer restrictions before proposing any trust settlement, to confirm that investor consent is obtainable for the specific structure proposed. Contact US-UK Tax at hello@us-uktax.com or call 0333-8807974 to begin a confidential founder succession planning review today.

Contact Us

US-UK Tax | hello@us-uktax.com | 0333-8807974

https://www.us-uktax.com

FAQs

Q: Do venture-backed startup shares qualify for UK business property relief?

Unquoted shares in trading companies generally qualify for 100% BPR after being held for two years. However, BPR can be denied where the company holds significant cash or investment assets relative to its trading activities — a risk that increases after a major funding round. A written BPR opinion should be obtained at each round, not assumed.

Q: How are startup shares valued for US estate tax purposes?

For US estate tax purposes, startup shares are valued at fair market value on the date of death using a methodology that accounts for the most recent funding round price, adjusted for discounts for lack of marketability, minority interest, and transfer restrictions in the shareholder agreement. A qualified independent valuation report is essential and can significantly reduce the US estate tax liability.

Q: Can a founder transfer startup equity to a trust during their lifetime?

Yes, but most shareholder agreements require investor consent for any share transfer, including transfers to family trusts. The transfer is a potentially exempt transfer for UK IHT if the founder survives for seven years and a taxable gift for US gift tax, requiring Form 709 reporting. The valuation at the time of the transfer determines the gift tax cost.

Q: What happens to unvested founder shares on death?

Unvested shares typically lapse at death under standard vesting agreements, while vested shares pass to the estate. The shareholder agreement may require the company or other shareholders to repurchase the deceased founder's shares rather than allowing free transfer to the estate. This provision can significantly affect the succession plan and must be reviewed before any planning is implemented.

Q: Does the US-UK Estate Tax Treaty help with founder equity succession?

Yes. The treaty provides a proportional credit that prevents the same startup shares from being subject to both the full UK IHT and the full US estate tax simultaneously. The credit reduces whichever country's tax is higher by the amount attributable to doubly-taxed assets. The treaty credit calculation must use consistent share values in both the UK IHT return and the US Form 706.

Q: When is the best time to set up a trust for founder equity?

The earliest practical stage — typically pre-Series A or at Series A before institutional investors establish a high valuation. At this stage, the gift tax value is lowest, the seven-year UK PET clock has the most time to run, and investor consent for the trust structure is easier to obtain. Waiting until a late-stage round or pre-IPO dramatically reduces the tax efficiency of the trust settlement.